BCTX vs. ACXP, VYNE, EYEN, NXTC, MRKR, IPA, VIRX, FBIO, THTX, and PMN
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Acurx Pharmaceuticals (ACXP), VYNE Therapeutics (VYNE), Eyenovia (EYEN), NextCure (NXTC), Marker Therapeutics (MRKR), ImmunoPrecise Antibodies (IPA), Viracta Therapeutics (VIRX), Fortress Biotech (FBIO), Theratechnologies (THTX), and ProMIS Neurosciences (PMN). These companies are all part of the "pharmaceutical preparations" industry.
BriaCell Therapeutics (NASDAQ:BCTX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk.
15.4% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 21.8% of BriaCell Therapeutics shares are held by company insiders. Comparatively, 35.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
BriaCell Therapeutics' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.
In the previous week, Acurx Pharmaceuticals had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Acurx Pharmaceuticals and 0 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 0.00 equaled Acurx Pharmaceuticals'average media sentiment score.
Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.
BriaCell Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.79, meaning that its stock price is 279% less volatile than the S&P 500.
Acurx Pharmaceuticals received 6 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 90.91% of users gave Acurx Pharmaceuticals an outperform vote.
BriaCell Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 714.48%. Acurx Pharmaceuticals has a consensus price target of $12.00, suggesting a potential upside of 519.55%. Given BriaCell Therapeutics' higher possible upside, analysts plainly believe BriaCell Therapeutics is more favorable than Acurx Pharmaceuticals.
Summary
BriaCell Therapeutics beats Acurx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
